An economist by training with a lengthy career in medtech and pharma, Benedikt von Braunmühl is well placed to provide a candid view of the contract development and manufacturing market. He took the helm of Rentschler Biopharma SE in September 2023 after the departure of Frank Mathias earlier in the year, who is now CEO of Oxford BioMedica plc.
Rentschler’s New CEO On 2024 Expectations For CDMOs
In Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).
More from Manufacturing Focus
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.